Merck's Tulisokibart Achieves Primary Endpoint in Hidradenitis Suppurativa Phase 2b Study

Merck & Co. Inc. (MRK) announced that its investigational therapy, Tulisokibart, met the primary endpoint in a Phase 2b clinical trial for the treatment of Hidradenitis Suppurativa (HS).

The study evaluated the efficacy of Tulisokibart in patients with moderate to severe HS. The primary endpoint was the percentage of patients achieving a 50 percent reduction in inflammatory skin lesions, known as the HiSCR50 response, at Week 16.

Results from the trial indicated that 72 percent of patients treated with Tulisokibart achieved the HiSCR50 response at Week 16. In comparison, 64 percent of patients treated with Tulisokibart achieved the same response. The placebo group saw a response rate of 35 percent.

Merck’s stock was trading at $149.81 at the time of the report.